What are the recommended treatment options for nocturnal enuresis, including behavioral measures and pharmacologic therapy?

Treatment of Nocturnal Enuresis

For uncomplicated monosymptomatic nocturnal enuresis in children ≥5 years, start with either enuresis alarm therapy (best for motivated families and children without nocturnal polyuria) or desmopressin 0.2-0.4 mg oral tablets 1 hour before bedtime (best for children with nocturnal polyuria and normal bladder capacity), after implementing basic lifestyle modifications. 1

Initial Assessment and Behavioral Foundation

Before any active treatment, all children require:

• Frequency-volume chart for ≥2 days measuring fluid intake, voided volumes, and documenting wet/dry nights for ≥1 week to identify nocturnal polyuria (>130% expected bladder capacity) and assess daytime bladder function 1
• Regular voiding schedule: morning, twice during school, after school, dinner time, and immediately before sleep 1
• Fluid management: Liberal intake during morning/early afternoon, restrict evening intake to ≤200 ml (6 oz), then nothing until morning 1
• Constipation treatment: Daily soft bowel movement without discomfort using polyethylene glycol if needed (grade Ia evidence) 1
• Dry/wet night calendar: Has independent therapeutic effect (grade Ib evidence) 1

Critical counseling point: Reassure families that bedwetting is neither the child's nor parents' fault, and treatment will continue until dryness is achieved 1

First-Line Treatment Selection Algorithm

Two evidence-based first-line options exist (grade Ia evidence for both):

Option 1: Enuresis Alarm Therapy

Best candidates:

• Well-motivated families willing to commit time and effort
• Children without nocturnal polyuria
• Children with reduced bladder capacity (maximum voided volume <70% expected for age) 1

Success rate: 50-70% during treatment with highest cure potential 1, 2

Key implementation: Requires high parental involvement and patience—families must understand this upfront to maintain compliance 3

Option 2: Desmopressin

Best candidates:

• Nocturnal polyuria (>130% expected bladder capacity)
• Normal bladder reservoir function (maximum voided volume >70% expected for age)
• Failed alarm therapy or families unlikely to comply with alarm 1

Dosing specifics:

• Oral tablets: 0.2-0.4 mg taken 1 hour before sleep (maximum effect at 1-2 hours)
• Oral melt formulation: 120-240 μg taken 30-60 minutes before bedtime
• Dose is not weight or age-dependent 1

Response: 30% full responders, 40% partial responders; effect is immediate 1

Critical safety warning: Risk of water intoxication with hyponatremia and convulsions if excessive fluid intake occurs. Polydipsia is an absolute contraindication. Nasal spray formulation should be avoided due to higher complication risk 1

Treatment strategy: Families can choose daily medication or use before important nights only. If daily use, implement regular short drug holidays to assess ongoing need 1

Second-Line Treatment for Therapy-Resistant Cases

If both alarm and desmopressin fail individually, proceed to anticholinergics (useful in ~40% of therapy-resistant children) 1

Prerequisites Before Anticholinergics:

1. Exclude/treat constipation
2. Complete frequency-volume chart
3. Perform uroflowmetry with ultrasound measurement of post-void residual to exclude dysfunctional voiding or urinary retention 1

Anticholinergic Dosing:

• Tolterodine: 2 mg at bedtime (may double if needed)
• Oxybutynin: 5 mg at bedtime (may double if needed)
• Propiverine: 0.4 mg/kg at bedtime (may double if needed)

Often requires combination with desmopressin at standard dose 1

Timeline: Anti-enuretic effect should appear within maximum 2 months, sometimes earlier 1

Side effects to monitor:

• Constipation (most bothersome; may herald decreasing efficacy)
• Post-void residual urine causing UTIs (most dangerous)
• Mood changes (less common with tolterodine/propiverine vs oxybutynin) 1

Family must monitor for dysuria or unexplained fever and maintain sound voiding habits 1

Third-Line Treatment: Imipramine

Reserved for tertiary care facilities only due to cardiotoxicity risk 1

Appropriate scenarios:

• Alarm therapy failed AND family cannot afford desmopressin
• All other treatments exhausted at specialized centers 1

Dosing:

• 25 mg at bedtime for children ≤9 years
• 50 mg at bedtime for children >9 years
• Evaluate after 1 month 1

Response rate: ~50% in both unselected and therapy-resistant children 1

Mandatory safety precautions:

• Exclude long QT syndrome with prolonged ECG if any history of palpitations, syncope, sudden cardiac death, or unstable arrhythmia in family 1
• Keep medication securely locked away from younger siblings—overdose can be fatal 1
• Regular drug holidays (≥2 weeks every 3 months) to prevent tolerance 1
• Can combine with desmopressin if partial response, but must restrict evening/night fluid intake 1

Side effects: Mood changes, nausea, insomnia (often appear before benefits but may resolve with continued treatment) 1

Treatment-Resistant Strategy

For children failing both first-line therapies:

1. Re-evaluate for non-monosymptomatic enuresis: Check for daytime symptoms, increased voiding frequency, urgency, or psychological comorbidities requiring screening 1
2. Verify proper alarm use: Many "failures" result from incorrect implementation 1
3. Retry alarm therapy after 2 years: Developmental maturation may enable success with previously failed alarm therapy 1
4. Consider alarm + desmopressin combination if nocturnal polyuria present 1

Common Pitfalls to Avoid

• Lifting/waking children at night: Allowed but not therapeutic beyond that specific night 1
• Starting treatment before age 6: Generally not recommended unless severe distress 1
• Desmopressin nasal spray: Higher risk of water intoxication; use oral formulations 1
• Anticholinergics as first-line: Only indicated after standard treatments fail and proper evaluation completed 1
• Inadequate follow-up: Monthly appointments to sustain motivation improve outcomes 1